Skip to main content
Top
Published in: Rheumatology International 3/2020

Open Access 01-03-2020 | Lymphoma | Comorbidities

Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren’s syndrome

Authors: Agata Sebastian, Marta Madej, Maciej Sebastian, Aleksandra Butrym, Patryk Woytala, Agnieszka Hałoń, Piotr Wiland

Published in: Rheumatology International | Issue 3/2020

Login to get access

Abstract

Lymphomas are one of the serious complications of the primary Sjörgen’s Syndrome (pSS). The aim of the study was to evaluate the frequency of lymphoma in pSS. The singe-center retrospective study included 198 Caucasian patients, who met diagnostic criteria for pSS. The type of lymphoproliferative disorder was classified according to the WHO 2016 classification. The mean time of observation, after pSS diagnosis, was 48 weeks. Focus score (FS) ≥ 1 was present in 85% of the patients, and anti-SSA antibodies were detected in 84%. Rheumatoid factor was detected in 130 (65%) patients. Mean disease activity index, according to EULAR Sjörgen’s Syndrome disease activity index (ESSDAI), was 8.3 points at the moment of pSS diagnosis. Complement C3 was decreased in 14% of the patients, while 10% showed reduced complement C4. Four patients (2%) were diagnosed with a lymphoma. Most of the patients were diagnosed with mucosa-associated lymphoid tissue lymphoma (MALT), in whom the tumour was located in the parotid gland, and in one patient the stomach was involved. Finally, one patient was diagnosed with a rare B-cell small lymphocytic lymphoma located in the lungs. In this article, we present detailed characteristics of each case. In analysed population the frequency of lymphoma in the course of pSS in patients with pSS is 2%. The variety of lymphoma types in pSS patients imposes individual monitoring in each patient at every check-up visit for disease activity.
Literature
1.
go back to reference Kassan SS, Thomas TL, Moutsopoulos HM et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888–892CrossRef Kassan SS, Thomas TL, Moutsopoulos HM et al (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89(6):888–892CrossRef
2.
go back to reference Theander E, Vasaitis L, Baecklund E et al (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 70(8):1363–1368CrossRef Theander E, Vasaitis L, Baecklund E et al (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome. Ann Rheum Dis 70(8):1363–1368CrossRef
3.
go back to reference Fox RI (2011) The importance of minor salivary gland biopsy in prediction of lymphoma in Sjögren's syndrome: should we be obtaining more information about prognosis from minor salivary gland samples? Ann Rheum Dis 70(8):1351–1353CrossRef Fox RI (2011) The importance of minor salivary gland biopsy in prediction of lymphoma in Sjögren's syndrome: should we be obtaining more information about prognosis from minor salivary gland samples? Ann Rheum Dis 70(8):1351–1353CrossRef
4.
go back to reference Johnsen SJ, Brun JG, Gøransson LG et al (2013) Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study. Arthritis Care Res (Hoboken) 65(5):816–821CrossRef Johnsen SJ, Brun JG, Gøransson LG et al (2013) Risk of non-Hodgkin's lymphoma in primary Sjögren's syndrome: a population-based study. Arthritis Care Res (Hoboken) 65(5):816–821CrossRef
5.
go back to reference Chiu YH, Chung CH, Lin KT et al (2017) Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study. Oncotarget 8(30):50098–50108CrossRef Chiu YH, Chung CH, Lin KT et al (2017) Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study. Oncotarget 8(30):50098–50108CrossRef
6.
go back to reference Voulgarelis M, Ziakas PD, Papageorgiou A (2012) Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) 91(1):1–9CrossRef Voulgarelis M, Ziakas PD, Papageorgiou A (2012) Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine (Baltimore) 91(1):1–9CrossRef
7.
go back to reference Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 61:554–558CrossRef Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 61:554–558CrossRef
8.
go back to reference Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76:9–16CrossRef Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76:9–16CrossRef
9.
go back to reference Choi SM, O'Malley DP (2018) Diagnostically relevant updates to the 2017 WHO classificationof lymphoid neoplasms. Ann Diagn Pathol 37:67–74CrossRef Choi SM, O'Malley DP (2018) Diagnostically relevant updates to the 2017 WHO classificationof lymphoid neoplasms. Ann Diagn Pathol 37:67–74CrossRef
10.
go back to reference Fisher BA, Jonsson R, Daniels T et al (2017) Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Ann Rheum Dis 76(7):1161–1168CrossRef Fisher BA, Jonsson R, Daniels T et al (2017) Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Ann Rheum Dis 76(7):1161–1168CrossRef
11.
go back to reference Seror R, Bootsma H, Saraux A et al (2016) Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75(2):382–389CrossRef Seror R, Bootsma H, Saraux A et al (2016) Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis 75(2):382–389CrossRef
12.
go back to reference Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3067CrossRef Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3067CrossRef
13.
go back to reference Brito-Zerón P, Kostov B, Fraile G et al (2017) Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol 10(1):90CrossRef Brito-Zerón P, Kostov B, Fraile G et al (2017) Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol 10(1):90CrossRef
14.
go back to reference Yachoui R, Leon C, Sitwala K, Kreidy M (2017) Pulmonary MALT lymphoma in patients with Sjögren's syndrome. Clin Med Res 15(1–2):6–12CrossRef Yachoui R, Leon C, Sitwala K, Kreidy M (2017) Pulmonary MALT lymphoma in patients with Sjögren's syndrome. Clin Med Res 15(1–2):6–12CrossRef
15.
go back to reference De Vita S, Gandolfo S (2019) Predicting lymphoma development in patients with Sjögren's syndrome. Expert Rev Clin Immunol 15(9):929–938CrossRef De Vita S, Gandolfo S (2019) Predicting lymphoma development in patients with Sjögren's syndrome. Expert Rev Clin Immunol 15(9):929–938CrossRef
16.
go back to reference Retamozo S, Brito-Zerón P, Ramos-Casals M (2019) Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus 28(8):923–936CrossRef Retamozo S, Brito-Zerón P, Ramos-Casals M (2019) Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus 28(8):923–936CrossRef
17.
go back to reference Baldini C, Ferro F, Luciano N, Bombardieri S, Grossi E (2018) Artificial neural networks help to identify disease subsets and to predict lymphoma in primary Sjögren’s syndrome. Clin Exp Rheumatol 112(3):137–144 Baldini C, Ferro F, Luciano N, Bombardieri S, Grossi E (2018) Artificial neural networks help to identify disease subsets and to predict lymphoma in primary Sjögren’s syndrome. Clin Exp Rheumatol 112(3):137–144
18.
go back to reference Lang J, Ma K, Guo J, Zhang J, Wang Q, Sun H (2018) Clinical significance of elevated antinuclear antibodies in patients with diffuse large B-cell lymphoma: a single center study. J Cancer Res Ther 14(1):213–219CrossRef Lang J, Ma K, Guo J, Zhang J, Wang Q, Sun H (2018) Clinical significance of elevated antinuclear antibodies in patients with diffuse large B-cell lymphoma: a single center study. J Cancer Res Ther 14(1):213–219CrossRef
19.
go back to reference Fang YF, Chen YF, Chung TT et al (2017) Hydroxychloroquine and risk of cancer in patients with primary Sjögren syndrome: propensity score matched landmark analysis. Oncotarget 8(46):80461–80471CrossRef Fang YF, Chen YF, Chung TT et al (2017) Hydroxychloroquine and risk of cancer in patients with primary Sjögren syndrome: propensity score matched landmark analysis. Oncotarget 8(46):80461–80471CrossRef
21.
go back to reference Vasaitis L, Nordmark G, Theander E et al (2018) Comparison of patients with and without preexisting lymphoma at diagnosis of primary Sjögren’s syndrome. Scand J Rheumatol 48(3):1–6 Vasaitis L, Nordmark G, Theander E et al (2018) Comparison of patients with and without preexisting lymphoma at diagnosis of primary Sjögren’s syndrome. Scand J Rheumatol 48(3):1–6
22.
go back to reference Brito-Zerón P, Retamozo S, Gandía M et al (2012) Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun 39(1–2):43–48CrossRef Brito-Zerón P, Retamozo S, Gandía M et al (2012) Monoclonal gammopathy related to Sjögren syndrome: a key marker of disease prognosis and outcomes. J Autoimmun 39(1–2):43–48CrossRef
23.
go back to reference Risselada AP, Kruize AA, Goldschmeding R et al (2014) The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome. Ann Rheum Dis 73(8):1537–1540CrossRef Risselada AP, Kruize AA, Goldschmeding R et al (2014) The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome. Ann Rheum Dis 73(8):1537–1540CrossRef
24.
go back to reference Fragkioudaki S, Nezos A, Souliotis VL et al (2017) MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. Sci Rep 7(1):7354CrossRef Fragkioudaki S, Nezos A, Souliotis VL et al (2017) MTHFR gene variants and non-MALT lymphoma development in primary Sjogren's syndrome. Sci Rep 7(1):7354CrossRef
25.
go back to reference Ogawa A, Ogawa Y, Mukai S et al (2019) Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with Sjögren's syndrome: case series. Medicine (Baltimore) 98(29):e16390CrossRef Ogawa A, Ogawa Y, Mukai S et al (2019) Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with Sjögren's syndrome: case series. Medicine (Baltimore) 98(29):e16390CrossRef
Metadata
Title
Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren’s syndrome
Authors
Agata Sebastian
Marta Madej
Maciej Sebastian
Aleksandra Butrym
Patryk Woytala
Agnieszka Hałoń
Piotr Wiland
Publication date
01-03-2020
Publisher
Springer Berlin Heidelberg
Keyword
Lymphoma
Published in
Rheumatology International / Issue 3/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04522-7

Other articles of this Issue 3/2020

Rheumatology International 3/2020 Go to the issue